MURFREESBORO, Tenn. — GreenWay Herbal Products LLC received U.S. Patent No. 12,496,307 from the United States Patent and Trademark Office. Issued December 16, 2025, the patent covers a 1-to-1 equimolar composition of cannabidiol (CBD) and cannabidiolic acid (CBDA) along with methods of use for treating inflammation and autoimmune diseases in humans and other mammals.
Titled Cannabinoid compositions and methods of using, the patent provides broad method-of-use protection for GreenWay’s proprietary cannabidiol and cannabidiolic acid formulation. Preclinical research conducted through GreenWay’s long-standing academic collaboration with Middle Tennessee State University (MTSU) indicated the equimolar composition may provide significantly greater activity than cannabidiol alone at suppressing cytokine storm activity in animal models.
The newly issued U.S. patent builds upon GreenWay’s expanding international intellectual property portfolio. Similar patents have already been granted in the United Kingdom, with corresponding applications pending in Canada, the European Union, Israel, and Thailand.
The U.S. claims include methods for treating inflammation and a non-exclusive list of autoimmune conditions including rheumatoid arthritis, Crohn’s disease, lupus erythematosus, multiple sclerosis, Sjögren syndrome, Graves’ disease, celiac disease, psoriatic disease, scleroderma, and autoimmune hepatitis.
GreenWay intends to leverage this protection to advance a regulated pharmaceutical development program under oversight by the U.S. Food and Drug Administration.
Related Articles:
